SCHEDULE: Adage Capital Discloses 5.14% Stake in Solid Biosciences
Beneficial Ownership Report
Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a 5.14% beneficial ownership stake in Solid Biosciences Inc.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross (collectively, the "Reporting Persons") have filed a Schedule 13G Amendment No. 1.
- The Reporting Persons beneficially own 4,000,000 shares of Common Stock of Solid Biosciences Inc.
- This ownership represents 5.14% of the outstanding Common Stock.
- The percentage is calculated based on 77,869,071 shares of Common Stock outstanding as of August 7, 2025, as reported in Solid Biosciences Inc.'s Quarterly Report on Form 10-Q for the period ended June 30, 2025.
- Adage Capital Management, L.P. is the investment manager, while Robert Atchinson and Phillip Gross are managing members of entities that control Adage Capital Management, L.P. and its general partner.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of beneficial ownership and does not contain explicit positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- The filing is a factual disclosure of beneficial ownership and does not contain explicit positives regarding Solid Biosciences Inc.'s operations or financial performance.
Negatives
- The filing is a factual disclosure of beneficial ownership and does not contain explicit negatives regarding Solid Biosciences Inc.'s operations or financial performance.
Risks
- The Reporting Persons certified that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of Solid Biosciences Inc.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Solid Biosciences Inc.'s future outlook.
Industry Context
This filing indicates a significant institutional investment in Solid Biosciences Inc., a biotechnology company, which is a common occurrence in the sector as investors take positions in companies with promising pipelines or market potential.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Certification of Intent | The Reporting Persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer. | 2025-11-13 | This certification clarifies the passive nature of the investment, indicating no immediate intent to engage in corporate governance changes or control contests. |
Stakeholder Impact
- Shareholders are informed of a significant institutional investor's stake in the company, which may be interpreted as a vote of confidence or increased institutional interest.
Key Dates
| Date | Description |
|---|---|
| 2025-06-30 | End of quarterly period for which Solid Biosciences Inc. filed its Form 10-Q. |
| 2025-08-07 | Date as of which 77,869,071 shares of Common Stock were outstanding, as reported in the Company's Form 10-Q. |
| 2025-08-12 | Date Solid Biosciences Inc. filed its Quarterly Report on Form 10-Q for the period ended June 30, 2025. |
| 2025-09-30 | Date of event which requires filing of this statement (beneficial ownership threshold met). |
| 2025-11-13 | Filing date of this Schedule 13G Amendment No. 1. |
Keywords
Solid Biosciences, Adage Capital Management, Beneficial Ownership, Schedule 13G, Institutional Investor, SGTX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.